Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15728413 | 0.82 | HCAR2 (0.42) | ALDH1A1MAPTCYP3A4NAMPTXDH | |
| SCHEMBL20073808 | 0.77 | NPC1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL162091 | 0.72 | HPGD (0.41) | MAPTCYP3A4NAMPTXDH | |
| SCHEMBL10399828 | 0.71 | — | — | |
| SCHEMBL18529294 | 0.71 | — | — | |
| SCHEMBL3582886 | 0.71 | — | — | |
| SCHEMBL8023464 | 0.71 | — | — | |
| SCHEMBL2427435 | 0.71 | — | — | |
| SCHEMBL18781606 | 0.71 | MEN1 (0.34) | — | |
| Ethane SCHEMBL28967597 | 0.69 | HPGD (0.39) | ALDH1A1MAPTCYP3A4NAMPTXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812105-B | Aminopyridyloxy pyrazole derivative, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-112812105-A | Aminopyridyloxypyrazole derivative and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | PIM1 244/4885APOBEC3G 1104/4885ALDH1A1 4827/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | PIM1 244/4885APOBEC3G 1104/4885ALDH1A1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.